Another Study Shows Link Between SSRIs and Birth Defects

Share this content:
Another Study Shows Link Between SSRIs and Birth Defects
Another Study Shows Link Between SSRIs and Birth Defects

THURSDAY, July 9, 2015 (HealthDay News) -- New research provides more evidence of a possible link between selective serotonin reuptake inhibitor (SSRI) antidepressant use early in pregnancy and a small increased risk of birth defects. The study appears online July 8 in The BMJ.

Studies in recent years have differed about the risk, if any, to babies born to women who take SSRIs during pregnancy. The new research examined statistics from 17,952 mothers of infants with birth defects and 9,857 other mothers. The children were born between 1997 and 2009. The researchers focused on SSRI use in the first three months of pregnancy.

The researchers found no connection between the SSRIs and nine birth defects that previously had been linked to them. However, they did link a higher risk of five birth defects to paroxetine and two birth defects to fluoxetine. The defects included conditions involving the heart, brain, skull, and abdominal wall. But the added risk was small, the researchers said.

"A woman's chance of having a child with the heart defect we described is about 10 per 10,000. Our results suggest that if she took paroxetine, that risk could increase to 24 per 10,000," study author Jennita Reefhuis, Ph.D., told HealthDay. Reefhuis is an epidemiologist with the U.S. National Center on Birth Defects and Developmental Disabilities at the U.S. Centers for Disease Control and Prevention.

Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »